Top Markets
Coin of the day
Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294
株式のランク #3529
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
株価
$4.64
時価総額
$5.18B
変化(1日)
0.41%
変化(1年)
-37.42%
CN
取引 Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

カテゴリー

Shenzhen Salubris Pharmaceuticals Co., Ltd.(002294)の株式分割履歴
Shenzhen Salubris Pharmaceuticals Co., Ltd.株(シンボル:002294)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 26, 2026に行われました。
Aug 26, 2026より前に購入された002294株は、現在0002294株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
3 x4
US
3 x20
FR
0 -
JP
6 x20
US
0 -
CH